<?xml version="1.0" encoding="UTF-8"?>
<p id="Par19">So far, most drugs used in paediatric patients seem to have no contraindications in COVID-19 [
 <xref ref-type="bibr" rid="CR50">50</xref>]. Some initial doubts regarding the safety of NSAIDs (e.g. ibuprofen) have been rejected by the WHO and EMA [
 <xref ref-type="bibr" rid="CR51">51</xref>] due to the lack of evidence on the association of their administration with a worse outcome of COVID-19. Nonetheless, recommendations may eventually change according to our better understanding of the disease. Evidence on these and other categories of patients are still to be obtained. Hence, a constant update of clinicians is required. Finally, due to the need of carefully monitoring their patients, child neurology specialists should consider that a helpful tool might be represented by telemedicine, which has been proven to obtain similar satisfaction rates and eventual outcomes compared with traditional visit for different diseases [
 <xref ref-type="bibr" rid="CR52">52</xref>â€“
 <xref ref-type="bibr" rid="CR54">54</xref>].
</p>
